Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03849716 · ClinicalTrials.gov registry record
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
A clinical trial of Dermatitis, Atopic, sponsored by Sanofi.
- Active
- Registry status
- 266
- Enrollment target
- 20
- Study locations
NCT03849716 is a study of Dermatitis, Atopic that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 266 participants, below the 388-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT03849716, a study of Dermatitis, Atopic, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- 266 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: * Disease state and time course of AD, * Disease state and evolution of selected atopic comorbid conditions, * Effectiveness of specific AD treatments.
Conditions Studied
Interventions
- OTHER Blood sample
- OTHER Cheek swab
Study Locations (20)
Florida
- Amedica Research Institute, Inc. Site Number : 8400067 - Hialeah
- Eastern Research, Inc. Site Number : 8400032 - Hialeah
- Vista Health Research, LLC Site Number : 8400034 - Miami
- Pediatric & Adult Research Center Site Number : 8400040 - Orlando
Alabama
- C Squared Research Center Site Number : 8400068 - Birmingham
- Cahaba Dermatology Site Number : 8400046 - Birmingham
- C2 Research Center, LLC Site Number : 8400071 - Montgomery
California
- Axis Clinical Trials Site Number : 8400025 - Los Angeles
- Madera Family Medical Group Site Number : 8400054 - Madera
- Fomat Medical Research, Inc. Site Number : 8400033 - Oxnard
Georgia
- Georgia Pollens Clinical Research Centers, Inc. Site Number : 8400057 - Albany
- IACT Health Site Number : 8400056 - Columbus
Illinois
- Northwestern University Feinberg School of Medicine Site Number : 8400001 - Chicago
- NorthShore University HealthSystem Site Number : 8400064 - Skokie
New York
- Philip Fried, M.D., PLLC Site Number : 8400029 - The Bronx
- Tiga Pediatrics, PC Site Number : 8400037 - The Bronx
Ohio
- Cincinnati Children's Hospital Medical Center Site Number : 8400017 - Cincinnati
- Dermatology Associates of Mid-Ohio Site Number : 8400052 - Marion
South Carolina
- MUSC Site Number : 8400013 - Charleston
- Allergic Disease and Asthma Research Center, PA Site Number : 8400048 - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2019-04-05 |
| Est. Completion | 2026-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03849716
The ClinicalTrials.gov registry entry for NCT03849716 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 388-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (31% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which Blood sample is the first listed.
NCT03849716 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03849716 about?
NCT03849716 is a clinical study titled "Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)". Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: * Disease state and time course of AD, * Disease state and evolution of selected atopic comorbid conditions, * Effectiveness of specific AD treatments.
What is the current status of trial NCT03849716?
This trial is currently active not recruiting. The enrollment target is 266 participants. The study started on 2019-04-05. Estimated completion is 2026-09-30.
What conditions does trial NCT03849716 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT03849716?
The interventions under investigation include: Blood sample (OTHER), Cheek swab (OTHER).
Who is sponsoring clinical trial NCT03849716?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03849716 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.